BACKGROUND: Enzymatic activity of mite, fungal, and bee venom allergens is thought to potentiate their allergenicity. Bla g 2 is a potent cockroach allergen, but despite sharing sequence homology with aspartic proteinases, it contains critical amino acid substitutions that impair proteolytic activity. The biologic function of Bla g 2 remains unclear. OBJECTIVE: We sought to investigate the effects of specific amino acid substitutions on enzymatic activity, and the peptide-binding capability of Bla g 2. METHODS: Site-directed mutagenesis was used to produce a recombinant Bla g 2 mutant (Mut) with corrected canonical triads and a flap region. Another mutant (MutF - ) was expressed after additional mutations in the flap region of Mut. Bla g 2 wild-type (Wt), Mut, and MutF - were assayed for aspartic proteinase activity, and Bla g 2 Wt was tested for pepstatin binding. RESULTS: Recombinant Bla g 2 Wt and Mut did not show enzymatic activity in a milk-clotting and hemoglobin assay. By using a modified hemoglobin assay, residual activity inhibited by pepstatin was detected for MutF - and Wt at 20 microg/mL, whereas pepsin was active at a 1000-fold lower concentration. Most of Bla g 2 binding to pepstatin-agarose was nonspecific. CONCLUSION: Residual proteolytic activity was found for Bla g 2 at concentrations of approximately 4 mM. This weak activity suggests that proteolysis is not the primary function of this allergen and that it is unlikely to contribute to the allergenicity of Bla g 2. Bla g 2 has a cleft that might specifically bind ligands other than pepstatin.
BACKGROUND: Enzymatic activity of mite, fungal, and bee venom allergens is thought to potentiate their allergenicity. Bla g 2 is a potent cockroach allergen, but despite sharing sequence homology with aspartic proteinases, it contains critical amino acid substitutions that impair proteolytic activity. The biologic function of Bla g 2 remains unclear. OBJECTIVE: We sought to investigate the effects of specific amino acid substitutions on enzymatic activity, and the peptide-binding capability of Bla g 2. METHODS: Site-directed mutagenesis was used to produce a recombinant Bla g 2 mutant (Mut) with corrected canonical triads and a flap region. Another mutant (MutF - ) was expressed after additional mutations in the flap region of Mut. Bla g 2 wild-type (Wt), Mut, and MutF - were assayed for aspartic proteinase activity, and Bla g 2 Wt was tested for pepstatin binding. RESULTS: Recombinant Bla g 2 Wt and Mut did not show enzymatic activity in a milk-clotting and hemoglobin assay. By using a modified hemoglobin assay, residual activity inhibited by pepstatin was detected for MutF - and Wt at 20 microg/mL, whereas pepsin was active at a 1000-fold lower concentration. Most of Bla g 2 binding to pepstatin-agarose was nonspecific. CONCLUSION: Residual proteolytic activity was found for Bla g 2 at concentrations of approximately 4 mM. This weak activity suggests that proteolysis is not the primary function of this allergen and that it is unlikely to contribute to the allergenicity of Bla g 2. Bla g 2 has a cleft that might specifically bind ligands other than pepstatin.
Authors: Judith A Woodfolk; Jill Glesner; Paul W Wright; Christopher L Kepley; Mi Li; Martin Himly; Lyndsey M Muehling; Alla Gustchina; Alexander Wlodawer; Martin D Chapman; Anna Pomés Journal: J Biol Chem Date: 2015-12-07 Impact factor: 5.157
Authors: Mi Li; Alla Gustchina; Jerry Alexandratos; Alexander Wlodawer; Sabina Wünschmann; Christopher L Kepley; Martin D Chapman; Anna Pomés Journal: J Biol Chem Date: 2008-06-02 Impact factor: 5.157
Authors: L Karla Arruda; Michelle C R Barbosa; Ana Beatriz R Santos; Adriana S Moreno; Martin D Chapman; Anna Pomés Journal: Curr Allergy Asthma Rep Date: 2014-04 Impact factor: 4.806
Authors: Anna Pomés; Geoffrey A Mueller; Thomas A Randall; Martin D Chapman; L Karla Arruda Journal: Curr Allergy Asthma Rep Date: 2017-04 Impact factor: 4.806
Authors: Mi Li; Alla Gustchina; Jill Glesner; Sabina Wünschmann; Lisa D Vailes; Martin D Chapman; Anna Pomés; Alexander Wlodawer Journal: J Immunol Date: 2010-12-01 Impact factor: 5.422
Authors: P Gao; D N Grigoryev; N M Rafaels; D Mu; J M Wright; C Cheadle; A Togias; T H Beaty; R A Mathias; J T Schroeder; K C Barnes Journal: Clin Exp Allergy Date: 2010-07-04 Impact factor: 5.018